3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
5
Phase 1/2
2
Phase NA
1
Phase 3
1
Phase 2/3
1
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Mastocytosis
1
Liver Neoplasms
1
Gastroenteropancreatic Neuroendocrine Tumors
1
GATA2 Deficiency
1
Colorectal Neoplasms
1
Advanced Solid Tumor
1
Interventions
Oxaliplatin
15
Fluorouracil
13
Bevacizumab
13
Leucovorin
10
Capecitabine
8
Folfox protocol
7
Irinotecan
6
IFL protocol
4
Cetuximab
4
Folic Acid
3
Aspirin
3
atezolizumab
2
XELOX
2
Surgical Procedures, Operative
2
Magnetic Resonance Spectroscopy
2
Drug Therapy
2
Chemotherapy, Adjuvant
2
trifluridine tipiracil drug combination
1
trametinib
1
titanium silicide
1
sulindac sulfone
1
spartalizumab
1
sacituzumab govitecan
1
regorafenib
1
raltitrexed
1
pertuzumab
1
irinotecan sucrosofate
1
folfirinox
1
envafolimab
1
dabrafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Colorectal Neoplasms
×
Injections
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled